Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

XII Contents
9.6 Loading DC with Antigens 186
9.7 Dose Delivery and Vaccination Schedule 187
9.8 Phase I/II Clinical Trials 188
9.9 Phase III Clinical Trials 193
9.10 Side Effects 194
9.11 Monitoring Immune Responses 194
9.12 Tumor Escape 195
9.13 New Developments in DC Immunotherapy 196
9.14 Conclusion 197
References 197
10 The Immune System in Cancer: If It Isn't Broken, Can We Fix It? 204
Richard G. Vile
10.1 Commitment and the Modern Immune System 204
10.2 Evolutionary Tuning 206
10.3 Tumor Antigens and Responses to Them 209
10.4 Antigen Presentation ± A Resume 209
10.5 Playing to Strengths 211
10.6 Exploiting Weaknesses: Autoimmunity 214
10.7 Combining the Best of Both Worlds 218
10.8 The Way Forward 221
Acknowledgments 223
Appendix: Glossary 223
References 225
11 Hybrid Cell Vaccination for Cancer Immune Therapy 230
Peter Walden, Gernot Stuhler and Uwe Trefzer
11.1 Introduction 230
11.2 Immunological Basis of the HCV Approach to Cancer Immune
Therapy 231
11.2.1 Tumor Antigenicity 231
11.2.2 T±T Cell Collaboration in the Induction of Cellular Cytotoxic Immune
Responses 233
11.3 Vaccination Strategies for Cancer Immune Therapy 235
11.4 HCV 236
11.4.1 Conceptual Basis 236
11.4.2 HCV in Preclinical Studies 237
11.4.3 Clinical Experience with HCV 238
11.5 Conclusion and Prospects 240
References 241
12 Principles and Strategies Employing Heat Shock Proteins
for Immunotherapy of Cancers 253
Zihai Li
12.1 The Thesis 253